Skip to main content
Figure 2 | Cancer & Metabolism

Figure 2

From: Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

Figure 2

In vitro metabolic analysis of PDAC cell lines. Basal oxygen consumption rates [OCR (pMoles/min/mg protein)] (a), proton production rates [PPR (pMoles/min/mg protein)] (b) and OCR/PPR (c) measurements acquired using XF96 for all three PDAC cell lines. Data presented as mean ± S.D. (d) Mitochondrial bioenergetics profile indicates SU.86.86 cells as more oxidative than Hs766t and MiaPaCa-2 cells. Oligo = 1 μM oligomycin, FCCP = 1 μM FCCP and Rot/Ant = 1 μM Rotenone and 1 μM Antimycin A. (e) Glycolytic bioenergetics profile shows MiaPaCa-2 and Hs766t cells exhibit a glycolytic phenotype in comparison to SU.86.86 cells. Gluc = 12 mM D-Glucose, Oligo = 1 μM Oligomycin and 2-DG = 50 mM 2-Deoxyglucose. (f-h) ΔOCR following dose dependent administration of exogenous sodium pyruvate. Data are presented as mean ± S.D of three replicate studies. A two-tailed Student’s t-test was used to determine significance. * p<0.05, ** p<0.01, ***, p<0.001, **** p<0.0001. See also Additional file 1: Figures 3 and 4. (i) Percent glucose uptake and (j) percent pyruvate uptake presented relative to T=0 substrate concentrations. Data are presented as mean ± S.D. of three replicates.

Back to article page